📰 Human Use News
Page 35 - Human Use News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Human Use. Real-time updates on events, politics, business and more.
November 6, 2023
06.11.2023 - Positive clinical data updates across multiple drug classes including antibody-drug conjugate (ADC) candidates BNT323/DB-1303, BNT325/DB-1305, CAR-T candidate BNT211, T cell therapy candidate BNT221 and mRNA cancer vaccine candidate BNT116Progress ...
November 6, 2023
/PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced financial results for the third quarter...
November 2, 2023
Imetelstat is currently under regulatory review by the FDA and EMA for the treatment of transfusion-dependent anemia in adult patients with lower risk MDS Planning is ongoing for a potential...
November 2, 2023
/PRNewswire/ -- Gedeon Richter Plc. (Richter) together with Sumitomo Pharma America, Inc. (SMPA) and Sumitomo Pharma Switzerland, GmbH (SMPS) today...
November 2, 2023
Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results SAN DIEGO, November 2, 2023- Cidara Therapeutics, Inc. , a biotechnology company...
November 2, 2023
SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company focused on developing targeted th...
November 1, 2023
Jena, Germany, November 1, 2023 - InflaRx N.V. , a biotechnology company pioneering anti-inflammatory therapeutics targeting the complement system, announced today financial results...
November 1, 2023
UCB presents latest data from generalized myasthenia gravis portfolio at 2023 AANEM Annual Meeting and MGFA Scientific Session 14 presentations - including 3...
November 1, 2023
Novavaxs updated COVID-19 vaccine is the only updated protein-based non-mRNA COVID-19 vaccine available in the European Union for individuals aged 12 and olderNovavax is working closely with EU...
November 1, 2023
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of elranatamab-bccm for the treatment of adult patients with relapsed/refractory multiple myeloma who were previously treated with 3 or more lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody, and who experienced disease progression on their last therapy.